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Abstract
Background—In certain parts of Africa, type-specific HSV type-2 ELISAs may have limited
specificity. To date, no study has been conducted to validate HerpeSelect and Kalon type-specific
HSV-2 ELISAs using both the Western blot (WB) and Recombinant gG ELISA inhibition testing
as reference standards.
Methods—A total of 120 HIV-seronegative men (aged 18-24 years) provided blood samples.
HSV-2 IgG serum antibodies were detected using four different methods: i. HerpeSelect HSV-2
ELISA (n=120), ii. Kalon HSV-2 ELISA (n=120), iii. University of Washington WB (n=101), and
iv. a recombinant inhibition test (n=93).
Results—HSV-2 seroprevalence differed significantly by HSV-2 detection method, ranging
from 24.8% with the WB to 69.8% with the HerpeSelect ELISA. Using the WB as the reference
standard, the HerpesSelect had the highest sensitivity for HSV-2 antibody detection (100%), yet
lowest specificity (40%). Similar results were obtained using the inhibition test as the reference
standard. The sensitivity and specificity of the Kalon test were 92% and 79%, respectively, versus
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the WB; and 80% and 82% versus the inhibition test. Using the inhibition test as the reference
standard, the sensitivity of the WB appeared low (49%).
Conclusions—In HIV-seronegative men in western Kenya, the HerpeSelect and Kalon type-
specific ELISAs had high sensitivities yet limited specificities using the WB as reference standard.
Overall, the Kalon ELISA performed better than the HerpeSelect ELISA in these young men from
Kisumu. Further understanding is needed for the interpretation of HSV-2 inhibition or ELISA test
positive/WB seronegative results. Before HSV-2 seropositivity may be reliably reported in
selected areas of Africa, performance studies of HSV-2 serological assays in individual
geographical areas are recommended.
Summary—Using Western-blot as the reference standard, sensitivity and specificity were 100%
and 40%, respectively for HSV-2 HerpeSelect, and 92% and 79% for HSV-2 Kalon ELISA among
men from Kisumu, Kenya.
Keywords
Herpes Simplex Virus Type-2; Performance; Serology; Africa
INTRODUCTION
Infection with herpes simplex virus type-2 (HSV-2) is a key risk factor for human
immunodeficiency virus-1 infection (hereafter, HIV) in sub-Saharan Africa (1). Serologic
testing for HSV-2 may be clinically useful in this setting and elsewhere as an indicator of an
individual’s risk of HIV infection, for accurate calculation of per-contact risk of
transmission of HIV, for differential diagnosis of genital ulcers, and potentially for
interventions which focus on HSV-2 status to prevent acquisition or transmission of HIV(1).
One of the most commonly used type-specific HSV-2 ELISAs in sub-Saharan Africa, the
HerpeSelect ELISA test [(Focus Diagnostics], has been shown to have poor specificity(2),
(3) when compared with the monoclonal antibody (MAb) ELISA and University of
Washington Western blot (WB) gold standard in specific African populations.
A study in five African countries found that the HSV-2 HerpeSelect yielded similar results
to the WB in samples from South Africa and Zimbabwe(4). However, samples from Kenya
and Uganda (4) were found to have higher HSV-2 positivity detected than the WB,
suggesting the possibility of false positive HerpeSelect HSV-2 results. Another possible
explanation is lower sensitivity of the WB assay. As there is potential for under-detection of
HSV-2 antibodies among recent seroconverters using the WB assay(5), additional
performance research has incorporated HSV-2 Recombinant gG ELISA inhibition testing as
an alternative reference gold-standard to the WB (4). This recombinant inhibition test
measures antibody binding to multiple epitopes of HSV-2 glycoprotein G (gG2), and uses
the differential absorption of type-specific antibodies to identify potential false-positive
results(4).
To evaluate the performance of HSV-2 serological testing among young, HIV-seronegative
men in Kisumu, Kenya, we conducted a study in the framework of a randomized controlled
trial (RCT) of male circumcision for the prevention of HIV infection(6). We present here the
performance of the type-specific HSV-2 HerpeSelect ELISA and Kalon HSV-2 (Kalon
Biological Ltd) ELISAs, compared to two confirmatory assays of the Western blot (WB)
and Recombinant gG ELISA inhibition testing.
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Study population and enrollment
Uncircumcised men aged 18 to 24 years of age in Kisumu, Kenya were invited to participate
in the RCT of male circumcision. The primary aim of this RCT was to determine the
effectiveness of male circumcision in reducing HIV incidence(6). Study participants were
recruited from sexually transmitted infection (STI) clinics, workplaces, and community
organizations. This study includes men who were initially screened to participate in the RCT
who consented to serological testing. Study inclusion criteria included being uncircumcised,
HIV seronegative, sexually active (defined as reporting sex within the last 12 months), and
having hemoglobin 9.0 g/100 mL, as previously described (6). Data analysis inclusion
required that samples be available for shipment to the University of Manitoba by early
February 2002. A total of 120 men completed the initial screening.
Type-specific HSV-2 HerpeSelect and Kalon ELISA serological testing was conducted at
the University Of Manitoba Department Of Medical Microbiology Laboratory in Winnipeg,
Canada, per manufacturer’s instructions (7;8). According to manufacturer’s instructions for
both assays, index values of <0.9 were classified as negative, those >1.1 as positive, and
otherwise as equivocal. Due to budget constraints, a total of 101 samples were randomly
chosen from the initial 120 collected for WB analyses conducted at the University of
Washington. Of the 19 samples without WB results, a total of 13 (68%) were HerpeSelect
seropositive, and 7 (37%) were Kalon seropositive. HSV inhibition testing, as previously
described (4), was conducted on a random sample of 100 samples at Focus Diagnostics in
Cypress, California. Briefly, for the latter, sera were absorbed with HSV-1 and HSV-2
antigen, and samples exhibiting 60% or greater inhibition with the HSV-2 antigen were
considered positive for HSV-2 antibody.
All study protocols were reviewed and approved by the Institutional Review Boards of the
University of Illinois at Chicago, University of Manitoba, University of Nairobi and the
University of North Carolina, and by RTI International.
The sensitivity and specificity were calculated for the i, Kalon ELISA, ii. HerpeSelect, and
iii. HerpeSelect followed by confirmation with the Kalon ELISA of HerpeSelect positive
samples. Summary receiver operating characteristic (ROC) curves were also estimated (9).
The ROC curves were plotted as sensitivity on the ordinate and 1-specificity (false positivity
rate) on the abscissa. Explanatory power of predictive models was quantified using the C-
statistic, which is equivalent to the area under the ROC curve in this context and is a
commonly used measure of model predictive power (10).
RESULTS
HSV-2 seroprevalence differed substantially by HSV-2 detection method among HIV-
seronegative men (aged 18-24 years), HerpeSelect and Kalon testing yielded 69.8% (83/119)
and 39.0% (46/118) seropositivity, after excluding 1 and 2 equivocal samples, respectively.
Of 101 WB testing results HSV-2 WB seropositivity was 24.8% (25/101), of which two
samples were classified as having atypical profiles to HSV-2 proteins. Of these 101 sera, 70
were positive by HerpeSelect (30 negative, 1 equivocal), and 39 were positive by Kalon (61
were negative, 1 equivocal) (using package insert standards for positivity). Of the 19
samples without WB results, HSV-2 results were similar to those with WB results: a total of
13 (68%) were HerpeSelect seropositive, and 7 (37%) were Kalon seropositive. Inhibition
testing among 100 samples yielded 45.2% seroprevalence (42/93) after excluding 7 samples
with equivocal results.
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As shown in Table 1, the HerpeSelect ELISA test had 100% sensitivity (25/25) but only
40% specificity (30/76) using WB as the reference standard. Kalon yielded a slightly lower
sensitivity (92%, 23/25) but a substantially higher specificity (79%, 60/76) versus the WB,
with the same manufacturer-specified cutoffs. In this setting, with a prevalence of
approximately 25% using WB as the gold standard, the HerpeSelect ELISA had a positive
predictive value (PPV) of 0.36 and negative predictive value (NPV) of1.0, and the Kalon
ELISA had a PPV of 0.59 and NPV of 0.97.
When WB results were negative, HerpeSelect and Kalon yielded concordant results in 46 of
74 cases (Table 2). In the remaining 28 cases, however, the Kalon test was negative while
the HerpeSelect test was positive. Among these WB-/HerpeSelect+/Kalon-discordant
samples, the median index value was 1.95 (range 1.15-7.43) for HerpeSelect [(mean=2.41
(SD=1.47)), and 0.44 (range 0.19-0.89) for Kalon [(mean 0.47 (SD 0.23)). Of the 46
concordant results, 30 were dually HerpeSelect and Kalon seronegative and 16 were dually
HerpeSelect and Kalon seropositive. Among these WB-/HerpeSelect+/Kalon+ samples, the
median index value was 5.70 (range 2.22-7.43) for HerpeSelect [(mean=5.17 (SD=1.98)),
and 2.37 (range 1.17-4.26) for Kalon [(mean= 2.38 (SD=0.93)). Among the 25 WB positive
sera, HerpeSelect and Kalon ELISAs were highly concordant. The only two sera with WB+/
HerpeSelect+/Kalon- results had index values of 1.24 and 4.83 for HerpeSelect, and 0.12
and 0.29 for Kalon.
Sensitivity and specificity were calculated for a variety of additional, dichotomous cutoffs
for both ELISA tests (Table 1). Using the WB as the reference gold-standard, the sensitivity
of the HerpeSelect ELISA was generally higher than that of Kalon up to a cut-off of 2.0,
although relative differences in sensitivity decreased with higher chosen diagnostic cut-offs
for both tests. The Kalon test had consistently higher specificity than the HerpeSelect
ELISA, with the exception of a chosen cut-off of 3.4, where the HerpeSelect ELISA
performed at a specificity of 80%, but with a lower sensitivity of 80%. Specificity for
HSV-2 detection was generally under 80% for both serological assays over a wide range of
investigated cut-offs. The Kalon optimized tradeoffs at a cutoff value of 1.2 (sensitivity
92%, specificity 80%), while the HerpeSelect ELISA optimized tradeoffs between
sensitivity and specificity at a dichotomous cutoff of 3.5 (sensitivity 80%, specificity 80%).
The combination of HerpeSelect ELISA and Kalon did not perform markedly better than use
of either test separately (Table 1).
Using the inhibition test as the reference standard and considering the manufacturer’s
suggested cutoffs, the HerpeSelect ELISA test had 100% sensitivity, but low specificity
(54%), while the Kalon test had sensitivity 80% and specificity 82%. The HerpeSelect
optimized sensitivity/specificity tradeoffs at the cutoff of 2.5 (sensitivity 74%, specificity
73%); Kalon optimized that tradeoff at a cutoff of 1.0 (81% and 82%). Again, the
combination of HerpeSelect ELISA and Kalon did not improve sensitivity and specificity.
Among sera with both WB and inhibition test results (n=76), the concordance between the
two tests was 74% (56/76.). Against the inhibition test, the WB had relatively lower
sensitivity than inhibition testing (48.6%), with high specificity (95.1%). In contrast, the
sensitivity and specificity of the inhibition test against WB were 89.5% and 68%,
respectively (data not shown).
Receiver operator characteristic (ROC) curve analysis using WB as the gold standard gave a
c-statistic of 0.833 for HerpeSelect, 0.869 for Kalon, and 0.880 for the two tests used
together. ROC curves for all three of these results using WB as gold standard are shown in
Figure 1. Using Inhibition as the gold standard yielded c-statistics of 0.806 for HerpeSelect
ELISA, 0.866 for Kalon, and 0.861 for both tests together.
Smith et al. Page 4














To our knowledge, this is the first study to compare the performance of both the HerpeSelect
and Kalon HSV-2 ELISA in African sera with two confirmatory assays of the Western blot
and inhibition testing. Among young men in Kisumu, HSV-2 seroprevalence varied notably
by the diagnostic method choice, ranging from 25% with the Western blot to 67% with the
HerpeSelect. Using the WB as the reference gold standard, the HerpeSelect and Kalon type-
specific ELISAs (employed per manufacturer’s instructions) had high sensitivities of over
90% (100% for HerpeSelect, 92% for Kalon). However, the specificity of the Kalon ELISA
(79%) was superior to that of the Herpes-Select ELISA(40%). When inhibition testing was
employed as an alternative reference standard, HSV-2 performance results were largely
comparable to those based on the WB reference gold-standard, with the exception of a
slightly lower sensitivity for Kalon.
These data complement previous studies of HSV-2 ELISA performance comparisons, in
particular by incorporating HSV-2 inhibition testing results. All assays consistently showed
low specificity of the HerpeSelect in Kisumu male sera when using the manufacturer’s
recommended cut-off. Among 330 samples from 4 African countries, Van Dyck et al. used
the Western blot and monoclonal antibody (MAb) ELISA to test samples found to be
initially discordant between the HerpeSelect ELISA and a monoclonal antibody test to
identify potential HSV-2 false positive results(12). A specificity of 57% was found for the
HerpeSelect among Kenyan samples. Hogrefe et al. examined 781 samples from 5 African
countries using the WB and HerpeSelect ELISA. Among WB/HerpeSelect discordant sera,
the inhibition assay was used and the specificity of sera from Kenya was found to be 93%
versus the WB and 97% versus the inhibition assay.(4) The differences in specificity results
between our data and Hogrefe et al.(4) may be related to populations studied, as no other
explanatory factor has been identified. It is worth noting that although the specificity of the
HerpeSelect ELISA has been found to be relatively low among populations with a low
HSV-2 seroprevalence (<5%) in the United States(13), or by geographical location (e.g.
Vietnam(14)), the specificity seen here in Kisumu is notably lower and may be specific to
certain geographical areas of Africa.
The present study indicated that the use of a higher HerpeSelect ELISA cut-off of 3.5, rather
than 1.1, would maximize overall HerpeSelect ELISA performance, but would sacrifice
sensitivity, which would be reduced to 80%. Our results are consistent with results from
Rakai, Uganda that found a cut-off of 3.4 for the HerpeSelect ELISA resulted in sensitivity
and specificity figures both of 85% when compared with Western blot.
Unlike a previous investigation in a population of Brazilian men at high risk of both HSV-2
and HIV (15), we did not find any advantage to retesting with the (more-specific) Kalon
ELISA after a positive HerpeSelect. Whether the WB or the inhibition test was chosen as the
reference standard in this Kenyan population, the combination of HerpeSelect followed by
Kalon retesting (according to manufacturer’s instructions) resulted in HSV-2 testing results
very similar to those found using a testing strategy of the Kalon ELISA alone, with about
80% test specificity. When an algorithm was chosen with a high cut-off of 3.4 for
HerpeSelect ELISA, followed by retesting of positive results with the Kalon ELISA at a cut-
off of 1.3, the sensitivity and specificity combination were still not higher than Kalon
ELISA testing alone,
Interpretation of HSV-2 serological assays is dependent upon the choice of the reference
“gold-standard”. PCR is considered the true gold-standard for HSV ascertainment, but does
not ascertain past exposure to HSV-2 (16). For HSV serological performance studies, the
well-validated WB is considered the reference standard of choice, but requires expertise for
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appropriate interpretation(17). The concordance between WB and inhibition test results of
74% was notably lower than the 95% concordance rate found in Hogrefe et al.’s study in
African sera(11). Further understanding, however, is needed for the interpretation of
samples in our Kenyan study that were i. WB-negative, and both HerpeSelect and Kalon
ELISA seropositive (n=16), and ii. WB-negative, and HerpeSelect positive and Kalon
ELISA seronegative (n=28), in order to determine whether the gold standard WB was
falsely negative. It is possible that a proportion of the “false positive” samples by either
ELISA may have actually been relatively recent HSV-2 seroconverters not detected by the
WB. The median time of HSV-2 seroconversion following documented primary HSV-2
infection has been shown to be the shortest for the HerpeSelect test (21 days) when
compared with the WB (40 days) or the Kalon ELISA (120 days)(5).
In these sera from young men in Kisumu, Kenya, the sensitivity of the WB may have been
sub-optimal. Another possible explanation for the lower specificity observed with
HerpeSelect is that it may have reacted to a variant strain of HSV-2 that was not detected by
either the WB or Kalon assays. Of note, HSV-2 sequences in patients with HSV-2 from sub-
Saharan Africa have not yet been well-studied and are not characterized in the GenBank
database (18). Potential differences in HSV-2 strain or variants resulting in abnormal WB
staining patterns could result in false-negative WB results. Alternatively, the HerpeSelect
ELISA may be cross-reactive with an unidentified non-HSV-2 virus to a greater extent than
the Kalon ELISA, although cross-reactive antibody may not necessarily have been due to
another infectious agent. Both HerpeSelect and Kalon ELISAs are based on gG-2 antigens
using a similar expression system, although sites of truncation of recombinant antigens used
in the two ELISAs are different.
Results presented here have several key advantages: the study included men at high-risk of
HSV-2 seroconversion, and laboratory testing was performed using four different type-
specific serological assays. A limitation of this study is that it is based on a small sample
size of young men from Kisumu, Kenya. Given that PPV and NPV values depend strongly
upon prevalence, these values are not generalizable outside of this study. Further, due to cost
constraints, a sub-set of sera was not tested with the Western blot, although HSV-2 ELISA
seroprevalence rates were similar among sera with and without WB testing results.
In this study of young men from western Kenya, the Kalon ELISA alone performed better
than the HerpeSelect ELISA, and there was no indication that any chosen algorithm for
combined type-specific ELISA testing resulted in preferential test results. Further
improvements in type-specific serological assays are needed for African sub-populations
where currently available tests have not shown optimal sensitivity and specificity.
Key messages
HSV-2 seroprevalence ranged from 24.8% with the Western blot, 39.0% with the Kalon
ELISA, to 69.8% with the HerpeSelect ELISA.
Using the Western blot as the reference standard, the HerpeSelect had the highest
sensitivity for HSV-2 antibody detection (100%), yet lowest specificity (40%). The
sensitivity and specificity of the Kalon test were 92% and 79%, respectively.
HerpeSelect and Kalon ELISAs had high sensitivities yet limited specificities in these
young men from Kenya.
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Table 2
Herpes Simplex Virus Type-2 Seropositivity for Western blot, HerpeSelect, and Kalon ELISA assay among
young men in Kisumu, Kenya
Western Blot status Number positive by HerpeSelect and Kalon status












Two samples excluded for equivocal HerpeSelect or Kalon results; 99 total samples included.
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